These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 18515798)
1. A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. Lin CP; Ban Y; Lyu YL; Desai SD; Liu LF J Biol Chem; 2008 Jul; 283(30):21074-83. PubMed ID: 18515798 [TBL] [Abstract][Full Text] [Related]
2. Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. Lin CP; Ban Y; Lyu YL; Liu LF J Biol Chem; 2009 Oct; 284(41):28084-28092. PubMed ID: 19666469 [TBL] [Abstract][Full Text] [Related]
3. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235 [TBL] [Abstract][Full Text] [Related]
4. Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex. Zhang HF; Tomida A; Koshimizu R; Ogiso Y; Lei S; Tsuruo T Cancer Res; 2004 Feb; 64(3):1114-21. PubMed ID: 14871846 [TBL] [Abstract][Full Text] [Related]
5. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Pommier Y Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698 [TBL] [Abstract][Full Text] [Related]
6. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Li TK; Houghton PJ; Desai SD; Daroui P; Liu AA; Hars ES; Ruchelman AL; LaVoie EJ; Liu LF Cancer Res; 2003 Dec; 63(23):8400-7. PubMed ID: 14679002 [TBL] [Abstract][Full Text] [Related]
7. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage. Adachi N; So S; Koyama H J Biol Chem; 2004 Sep; 279(36):37343-8. PubMed ID: 15218034 [TBL] [Abstract][Full Text] [Related]
8. SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. Mao Y; Sun M; Desai SD; Liu LF Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4046-51. PubMed ID: 10759568 [TBL] [Abstract][Full Text] [Related]
9. PARylation prevents the proteasomal degradation of topoisomerase I DNA-protein crosslinks and induces their deubiquitylation. Sun Y; Chen J; Huang SN; Su YP; Wang W; Agama K; Saha S; Jenkins LM; Pascal JM; Pommier Y Nat Commun; 2021 Aug; 12(1):5010. PubMed ID: 34408146 [TBL] [Abstract][Full Text] [Related]
10. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Tomicic MT; Kaina B Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513 [TBL] [Abstract][Full Text] [Related]
11. Transcriptomic Analysis of CRISPR/Cas9-Mediated PARP1-Knockout Cells under the Influence of Topotecan and TDP1 Inhibitor. Dyrkheeva NS; Malakhova AA; Zakharenko AL; Okorokova LS; Shtokalo DN; Pavlova SV; Medvedev SP; Zakian SM; Nushtaeva AA; Tupikin AE; Kabilov MR; Khodyreva SN; Luzina OA; Salakhutdinov NF; Lavrik OI Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982223 [TBL] [Abstract][Full Text] [Related]
12. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542 [TBL] [Abstract][Full Text] [Related]
13. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666 [TBL] [Abstract][Full Text] [Related]
14. Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase 1 DNA-protein crosslinks and 3'-blocking lesions in the absence of tyrosyl-DNA phosphodiesterase 1 (TDP1). Tsuda M; Kitamasu K; Kumagai C; Sugiyama K; Nakano T; Ide H DNA Repair (Amst); 2020; 91-92():102849. PubMed ID: 32460231 [TBL] [Abstract][Full Text] [Related]
15. Topoisomerase I-driven repair of UV-induced damage in NER-deficient cells. Saha LK; Wakasugi M; Akter S; Prasad R; Wilson SH; Shimizu N; Sasanuma H; Huang SN; Agama K; Pommier Y; Matsunaga T; Hirota K; Iwai S; Nakazawa Y; Ogi T; Takeda S Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14412-14420. PubMed ID: 32513688 [TBL] [Abstract][Full Text] [Related]
16. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Ando K; Shah AK; Sachdev V; Kleinstiver BP; Taylor-Parker J; Welch MM; Hu Y; Salgia R; White FM; Parvin JD; Ozonoff A; Rameh LE; Joung JK; Bharti AK Oncotarget; 2017 Jul; 8(27):43733-43751. PubMed ID: 28415827 [TBL] [Abstract][Full Text] [Related]
17. Neutral Porphyrin Derivative Exerts Anticancer Activity by Targeting Cellular Topoisomerase I (Top1) and Promotes Apoptotic Cell Death without Stabilizing Top1-DNA Cleavage Complexes. Das SK; Ghosh A; Paul Chowdhuri S; Halder N; Rehman I; Sengupta S; Sahoo KC; Rath H; Das BB J Med Chem; 2018 Feb; 61(3):804-817. PubMed ID: 29290109 [TBL] [Abstract][Full Text] [Related]
18. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631 [TBL] [Abstract][Full Text] [Related]
19. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. Pourquier P; Pilon AA; Kohlhagen G; Mazumder A; Sharma A; Pommier Y J Biol Chem; 1997 Oct; 272(42):26441-7. PubMed ID: 9334220 [TBL] [Abstract][Full Text] [Related]
20. ISG15 as a novel tumor biomarker for drug sensitivity. Desai SD; Wood LM; Tsai YC; Hsieh TS; Marks JR; Scott GL; Giovanella BC; Liu LF Mol Cancer Ther; 2008 Jun; 7(6):1430-9. PubMed ID: 18566215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]